Apimeds Pharmaceuticals US (APUS) Other Accumulated Expenses (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Other Accumulated Expenses came in at $100.0 in Q3 2025, little changed on a QoQ basis from $100.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Other Accumulated Expenses data on file, last reported at $100.0 in Q3 2025.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $100.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $100.0 (changed N/A YoY) and the FY2024 annual result came in at $76500.0, changed N/A from the prior year.
- Other Accumulated Expenses was little changed at $100.0 in Q3 2025, from $100.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $93700.0 in Q1 2025 to a low of $100.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Apimeds Pharmaceuticals US | 7.35 Mn | 7.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 100.00 |
| Jun 30, 2025 | 100.00 |
| Mar 31, 2025 | 93,700.00 |
| Dec 31, 2024 | 76,500.00 |